- Home
- SST vs ABP Comparison
SST vs ABP Comparison
Compare SST & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SST | ABP |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 12.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SST | ABP |
|---|---|---|
| Price | $3.26 | $0.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 7.0K | ★ 4.0M |
| Earning Date | 03-09-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $289,784,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 50.00 |
| 52 Week Low | $2.90 | $1.12 |
| 52 Week High | $15.00 | $34.65 |
Technical Indicators
Market Signals| Indicator | SST | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 20.43 |
| Support Level | $3.45 | $1.44 |
| Resistance Level | $4.25 | $2.89 |
| Average True Range (ATR) | 0.22 | 0.39 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 17.13 | 0.48 |
Price Performance
Historical ComparisonAbout SST System1 Inc.
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
About ABP Abpro Holdings Inc
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.